US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

62.24

-2.3600-3.65%

Post-market: 63.501.26+2.02%19:59 EDT

Volume:1.58M

Turnover:99.30M

Market Cap:6.57B

PE:50.60

High:65.40

Open:64.60

Low:61.94

Close:64.60

Loading ...

Overview Company News Filings

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism

MT Newswires Live

Corcept Therapeutics presents results from relacorilant study

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism

THOMSON REUTERS

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Corcept Therapeutics (CORT) Receives a Buy from Truist Financial

Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study

Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes

MT Newswires Live

Corcept Therapeutics Inc - Catalyst Met Its Primary Endpoint

THOMSON REUTERS

Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects

THOMSON REUTERS

Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

THOMSON REUTERS

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires Live

Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages

Corcept Phase 2 Trial of Dazucorilant for Amyotrophic Lateral Sclerosis Fails to Meet Primary Endpoint

MT Newswires Live

Corcept Therapeutics Fall 7% After ALS Drug Fails Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CORT/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CORT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CORT\",,,,,undefined,":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":62.24,"timestamp":1744920000000,"preClose":64.6,"halted":0,"volume":1579126,"hourTrading":{"tag":"盘后","latestPrice":63.5,"preClose":62.24,"latestTime":"19:59 EDT","volume":38950,"amount":2424670.8391,"timestamp":1744934398323},"delay":0,"floatShares":86953354,"shares":105503432,"eps":1.23,"marketStatus":"Market Closed","change":-2.36,"latestTime":"04-17 16:00:00 EDT","open":64.6,"high":65.395,"low":61.935,"amount":99298973.805736,"amplitude":0.05356,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.23,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":64.6,"preHourTrading":{"tag":"盘前","latestPrice":64.65,"preClose":64.6,"latestTime":"09:29 EDT","volume":1281,"amount":82922.69118000001,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":63.5,"preClose":62.24,"latestTime":"19:59 EDT","volume":38950,"amount":2424670.8391,"timestamp":1744934398323},"volumeRatio":1.1787014058847518,"impliedVol":0.6686,"impliedVolPercentile":0.5618},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CORT\",,,,,undefined,":{"symbol":"CORT","floatShares":86953354,"roa":"11.71%","roe":"23.81%","lyrEps":1.353582,"volumeRatio":1.1787014058847518,"shares":105503432,"dividePrice":0,"high":65.395,"amplitude":0.05356,"preClose":64.6,"low":61.935,"week52Low":20.84,"pbRate":"9.66","psRate":"9.73","week52High":117.33,"institutionHeld":0.7266,"latestPrice":62.24,"eps":1.23,"divideRate":0,"volume":1579126,"delay":0,"ttmEps":1.23,"open":64.6,"prevYearClose":50.39,"prevWeekClose":68.62,"prevMonthClose":114.22,"prevQuarterClose":114.22,"fiveDayClose":67.73,"twentyDayClose":57.59,"sixtyDayClose":59.03},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CORT\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2495050134","title":"Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism","url":"https://stock-news.laohu8.com/highlight/detail?id=2495050134","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495050134?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:15","pubTimestamp":1735596900,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., December 30, 2024----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application  to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism .Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism’s signs and symptoms, with an acceptable safety burden. Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia or QT prolongation – serious adverse events that can arise in p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-submits-drug-application-relacorilant-221500552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","BK4532","BK4007","LU0566484027.USD","LU1559883803.SGD"],"gpt_icon":0},{"id":"2494099100","title":"Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2494099100","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494099100?lang=en_us&edition=fundamental","pubTime":"2024-12-25 12:13","pubTimestamp":1735100026,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025.In this article, we are going to take a look at where Corcept Therapeutics Incorporated  stands against the other stocks that will make you rich in 2025.Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025. His analysis reflects cautious optimism, emphasizing potential growth and significant risks. Timmer described 2024 as a \"Goldilocks\" year for U.S. stock returns, characterized by robust earnings growth and rising valuations. The S&P 500 Index experienced a substantial increase, concluding the year with a gain of approximately 28% as it reached new all-time highs. This performance was driven by strong earnings from major companies, particularly the so-called \"Magnificent Seven\" stocks whose growth has significantly influenced the overall market dynamics.Why do we care about what hedge funds do?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hv8fBYqg8Dgag0OJoFlitA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d26c9db235b3dbe42cdfe14837da60f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hv8fBYqg8Dgag0OJoFlitA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d26c9db235b3dbe42cdfe14837da60f9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-incorporated-cort-rich-041346837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","PSQ","TQQQ","TSYW.SI","LU1559883803.SGD","QID","USAW.SI",".IXIC","LU0566484027.USD","NVIW.SI","NQmain","USJW.SI","QLD","CORT","BK4007","BK4532","MNQmain"],"gpt_icon":1},{"id":"2493081346","title":"Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493081346","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493081346?lang=en_us&edition=fundamental","pubTime":"2024-12-24 19:20","pubTimestamp":1735039207,"startTime":"0","endTime":"0","summary":"Launched on 02/23/2016, the Janus Henderson Small Cap Growth Alpha ETF  is a smart beta exchange traded fund offering broad exposure to the Style Box - Small Cap Growth category of the market.For a long time now, the ETF industry has been flooded with products based on market capitalization weighted indexes, which are designed to represent the broader market or a particular market segment.Market cap weighted indexes work great for investors who believe in market efficiency. They provide a low-cost, convenient and transparent way of replicating market returns.However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta.Non-cap weighted indexes try to choose stocks that have a better chance of risk-return performance, which is based on specific fundamental characteristics, or a mix of other such characteristics.The ETF return is roughly 13.16% and was u","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/janus-henderson-small-cap-growth-112007979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DOCS","BK4588","BK4532","BK4167","LU1559883803.SGD","JHG","LU0566484027.USD","BK4551","FDN","BK4585","BK4187","BK4550","DRS","IWO","JSML","BK4007","VBK","BK4135","CORT","BK4539"],"gpt_icon":0},{"id":"2491949066","title":"Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism","url":"https://stock-news.laohu8.com/highlight/detail?id=2491949066","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491949066?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:29","pubTimestamp":1734359363,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  said Monday that results from its phase 3 study of relacorilant to treat patients suffering from endogenous hypercortisolism showed clinically \"meaningful and durable cardiometabolic improvements.\"Hypercortisolism, or Cushing's syndrome, occurs when the body produces too much cortisol, which can cause high blood pressure leading to increased cardiovascular risk and mortality.At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure and mean diastolic blood pressure, compared with their measurement at entry into the long-term extension study, the company said.Relacorilant was well-tolerated, with a treatment duration of up to six years, the company added. It also said it will use the data to support a new-drug application with the US Food and Drug Administration, which it expects to submit this month.Shares of Corcept Therapeutics were up 2% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4532","CORT","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0},{"id":"2491231691","title":"Corcept Therapeutics presents results from relacorilant study","url":"https://stock-news.laohu8.com/highlight/detail?id=2491231691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491231691?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:11","pubTimestamp":1734358281,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-results-from-relacorilant-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-results-from-relacorilant-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU1559883803.SGD","CORT","LU0566484027.USD","BK4532"],"gpt_icon":0},{"id":"2491928693","title":"Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism","url":"https://stock-news.laohu8.com/highlight/detail?id=2491928693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491928693?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0PF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","CORT","BK4532"],"gpt_icon":0},{"id":"2491693122","title":"Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693122","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693122?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease . 116 patients with hypercortisolism were enrolled with treatment duration of up to six years. Results provide further evidence of relacorilant’s potential benefit as a treatment for patients with hypercortisolism. The Phase 3 long-term extension study enrolled 116 patients who had previously completed either Corcept’s Phase 3 GRACE or GRADIENT studies or its Phase 2 study in hypercortisolism. Patients experienced further improvement in blood pressure while maintaining response in other cardiometabolic measures, such as glycemic control and body weight. Consistent with its known safety profile, relacorilant was well-tolerated with a treatment duration of up to six years.\"People living with hypercortisolism are at risk of serious cardiometabolic comorbidities, including hypertension and hyperg","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w.w_ouLUJ_Z7kseBRn1TUg--~B/aD0yMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/74b91d26e60b84bff57712e80fb29d32","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w.w_ouLUJ_Z7kseBRn1TUg--~B/aD0yMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/74b91d26e60b84bff57712e80fb29d32"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-phase-3-long-term-130000519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4532","CORT","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0},{"id":"2491780413","title":"Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491780413","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491780413?lang=en_us&edition=fundamental","pubTime":"2024-12-13 21:53","pubTimestamp":1734097988,"startTime":"0","endTime":"0","summary":"On Thursday, Corcept Therapeutics Incorporated  said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlymin patients with hypercortisolism  and difficult-to-control type 2 diabetes.Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue, and weak muscles.Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast. CATALYST is a prospective Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1,057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5% despite receiving optimal therapies, including GLP-1 agonists.Patients who received Kor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e1h7CWrKKwNVUMxbKgiltg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ece19e53408aeb62e0f73a92c9753b9a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e1h7CWrKKwNVUMxbKgiltg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ece19e53408aeb62e0f73a92c9753b9a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-fda-approved-korlym-135308960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","BK4532","CORT","LU0566484027.USD","BK4007"],"gpt_icon":0},{"id":"2491321351","title":"Corcept Therapeutics (CORT) Receives a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491321351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491321351?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:16","pubTimestamp":1734092213,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed yesterday at $56.33. According to TipRanks,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/corcept-therapeutics-cort-receives-a-buy-from-truist-financial-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/corcept-therapeutics-cort-receives-a-buy-from-truist-financial-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","CORT","BK4532","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"2491636344","title":"Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2491636344","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491636344?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:47","pubTimestamp":1734043620,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study.The pharmaceutical company on Thursday said that the safety profile of Korlym in the study was consistent with the medication's label and no new side effects or adverse events were identified.Complete results from the study will be presented at a medical conference next year, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","CORT","LU1559883803.SGD","BK4007","BK4532"],"gpt_icon":0},{"id":"2491570253","title":"Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491570253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491570253?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:54","pubTimestamp":1734040458,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.Corcept said complete results will be presented at a medical conference in 2025.Shares of Corcept were up 0.8% in recent after-hours activity.Price: 56.80, Change: +0.47, P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","LU1559883803.SGD","LU0566484027.USD","CORT","BK4007"],"gpt_icon":0},{"id":"2491735464","title":"Corcept Therapeutics Inc - Catalyst Met Its Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2491735464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491735464?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA7MQW8S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","CORT","BK4532","BK4007"],"gpt_icon":0},{"id":"2491535464","title":"Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2491535464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491535464?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA7MQW8S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2491354514","title":"Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354514?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA7MQW8S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU0566484027.USD","BK4532","CORT","LU1559883803.SGD"],"gpt_icon":0},{"id":"2491366981","title":"Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491366981","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491366981?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., December 12, 2024----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym in patients with hypercortisolism  and difficult-to-control type 2 diabetes.CATALYST is a prospective, Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5 percent despite receiving optimal therapies, including GLP-1 agonists. Of these patients, 23.8 percent were identified as having hypercortisolism and were eligible to enter CATALYST’s treatment phase, in which 136 patients were randomized, 2:1, to receive","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SILcvSD6shA8n8Ub._ixiQ--~B/aD0yMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9712ae136f9853143c6875e3cf6c9c22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SILcvSD6shA8n8Ub._ixiQ--~B/aD0yMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9712ae136f9853143c6875e3cf6c9c22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-announces-positive-results-treatment-210500555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CORT","BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"2491336030","title":"CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2491336030","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491336030?lang=en_us&edition=fundamental","pubTime":"2024-12-12 23:21","pubTimestamp":1734016860,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis , a degenerative neurologic disorder.The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant  for treating patients with ALS.The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised  in patients treated with dazucorilant versus those treated with placebo.Shares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.Year to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.Data from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.Upon completing the study, patients were eligible to e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4007","CORT","SPRO","BK4196","CSTL","LU1559883803.SGD","IMCR","BK4505","BK4139","BK4532"],"gpt_icon":0},{"id":"2490269389","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2490269389","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490269389?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:07","pubTimestamp":1734012446,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Thursday, with The Health Care Select Sector SPDR Fund (XLV) marginally higher and the iShares Biotechnology ETF (IBB) down 0.1%.Keros Therapeutics (KROS) shares","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0130517989.USD","LU0477156953.USD","CNC","BK4581","LU1291159041.SGD","LU0130102774.USD","IBB","BK4007","LU0648001328.SGD","BK4585","BK4588","LU2362541273.HKD","LU2362540622.SGD","LU0566484027.USD","KROS","XLV","BK4139","BK4532","LU1989771016.USD","LU2362541513.USD","LU0130103400.USD","LU1201861165.SGD","IE0034235188.USD","LU0980610538.SGD","LU0130518102.USD","CORT","LU0648000940.SGD","LU0477156797.USD","BK4154","LU1201861249.SGD","LU1559883803.SGD","LU1699723380.USD"],"gpt_icon":0},{"id":"2490634804","title":"Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=2490634804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490634804?lang=en_us&edition=fundamental","pubTime":"2024-12-12 19:55","pubTimestamp":1734004514,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6. Edward Nash’s rating is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-outlook-for-corcept-therapeutics-amid-promising-developments-and-regulatory-advantages?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-outlook-for-corcept-therapeutics-amid-promising-developments-and-regulatory-advantages?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2490819565","title":"Corcept Phase 2 Trial of Dazucorilant for Amyotrophic Lateral Sclerosis Fails to Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2490819565","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490819565?lang=en_us&edition=fundamental","pubTime":"2024-12-12 06:25","pubTimestamp":1733955911,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  said late Wednesday a phase 2 trial assessing two doses -- 150 milligrams and 300 milligrams -- of dazucorilant in people with amyotrophic lateral sclerosis didn't meet its primary endpoint.The primary endpoint was the change from baseline in the amyotrophic lateral sclerosis functional rating scale-revised in people who were given dazucorilant compared with those who received placebo, the company said.The company also said people who were administered dazucorilant \"experienced substantially more gastrointestinal upset at the onset of treatment than those who received placebo.\"Upon completion of the 24-week study, patients were eligible to enter a long-term extension study in which they were given 300 milligrams of dazucorilant, the company said.Corcept said the long-term extension study will proceed and overall survival will be evaluated in March 2025.The shares of Corcept Therapeutics were falling 2% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0566484027.USD","CORT","BK4532","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"2490981591","title":"Corcept Therapeutics Fall 7% After ALS Drug Fails Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490981591","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490981591?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:49","pubTimestamp":1733953740,"startTime":"0","endTime":"0","summary":"Share of Corcept Therapeutics fell in late trading Wednesday after the company said its drug, dazucorilant, failed a recent Phase 2 trial.Shares slid 4.7% after hours to $57.26. Through Wednesday's close, the stock has roughly doubled over the past year.Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS. Patients who received the treatment experienced far more gastrointestinal upset at the start of the treatment than those who took the placebo.There were no deaths among patients who took the drug during the 24-week trial. In the placebo group, five patients died. The company will continue to assess overall survival rates in March 2025 when patients will have been receiving treatment for a full year.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Corcept Therapeutics Fall 7% After ALS Drug Fails Trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4532","BK4007","LU0566484027.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CORT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-26","symbol":"CORT","fiscalQuarterEnding":"2024/12","expectedEps":0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740546000000,"reportTimeType":"post","actualEps":0.26},{"market":"US","date":"2024-10-30","symbol":"CORT","fiscalQuarterEnding":"2024/09","expectedEps":0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730260800000,"reportTimeType":"post","actualEps":0.41},{"market":"US","date":"2024-07-29","symbol":"CORT","fiscalQuarterEnding":"2024/06","expectedEps":0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722225600000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2024-05-01","symbol":"CORT","fiscalQuarterEnding":"2024/03","expectedEps":0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714536000000,"reportTimeType":"post","actualEps":0.25},{"market":"US","date":"2024-02-15","symbol":"CORT","fiscalQuarterEnding":"2023/12","expectedEps":0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1707973200000,"reportTimeType":"post","actualEps":0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CORT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CORT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1700107200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CORT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CORT","date":"2025-04-17","current":48.265491,"percent":0.978896,"low":12.617742,"twenty":20.286086,"median":24.779141,"eighty":29.454515,"high":85.338767,"avg":26.190148,"sd":7.915387,"marketCap":6815521707},"quantilePoints":[{"date":"2020-04-24","current":15.988097,"twenty":-29.662778,"median":10.039278,"eighty":18.080162,"marketCap":1505774949},{"date":"2020-05-01","current":14.845254,"twenty":-29.662778,"median":10.16729,"eighty":18.080162,"marketCap":1398140837},{"date":"2020-05-08","current":14.523657,"twenty":-29.662778,"median":10.246957,"eighty":18.080162,"marketCap":1539100938},{"date":"2020-05-15","current":15.20496,"twenty":-29.662778,"median":10.402606,"eighty":18.080162,"marketCap":1611300014},{"date":"2020-05-22","current":17.032583,"twenty":-29.662778,"median":10.509751,"eighty":18.080162,"marketCap":1804976901},{"date":"2020-05-29","current":16.372908,"twenty":-29.662778,"median":10.517599,"eighty":18.080162,"marketCap":1735069859},{"date":"2020-06-05","current":15.345546,"twenty":-29.662778,"median":10.570633,"eighty":18.080162,"marketCap":1626198236},{"date":"2020-06-12","current":15.788934,"twenty":-29.662778,"median":10.632312,"eighty":18.080162,"marketCap":1673184936},{"date":"2020-06-19","current":17.503007,"twenty":-29.662778,"median":10.674036,"eighty":18.080162,"marketCap":1854828643},{"date":"2020-06-26","current":18.005874,"twenty":-29.662778,"median":10.737672,"eighty":18.13832,"marketCap":1908118438},{"date":"2020-07-02","current":18.579034,"twenty":-29.662778,"median":10.816326,"eighty":18.1602,"marketCap":1968857343},{"date":"2020-07-10","current":17.838251,"twenty":-29.662778,"median":10.956625,"eighty":18.168521,"marketCap":1890355173},{"date":"2020-07-17","current":17.82203,"twenty":-29.662778,"median":11.143818,"eighty":18.168521,"marketCap":1888636147},{"date":"2020-07-24","current":17.421899,"twenty":-29.662778,"median":11.212718,"eighty":18.178004,"marketCap":1846233515},{"date":"2020-07-31","current":16.167436,"twenty":-29.662778,"median":11.288088,"eighty":18.178004,"marketCap":1713295534},{"date":"2020-08-07","current":14.116479,"twenty":-29.662778,"median":11.383285,"eighty":18.178004,"marketCap":1610873724},{"date":"2020-08-14","current":13.939263,"twenty":-29.662778,"median":11.447928,"eighty":18.178004,"marketCap":1590651134},{"date":"2020-08-21","current":13.078502,"twenty":-29.662778,"median":11.607146,"eighty":18.178004,"marketCap":1492427127},{"date":"2020-08-28","current":12.769641,"twenty":-29.662778,"median":11.77016,"eighty":18.178004,"marketCap":1457182042},{"date":"2020-09-04","current":20.232944,"twenty":-29.662778,"median":12.0681,"eighty":18.192931,"marketCap":2308841966},{"date":"2020-09-11","current":17.964586,"twenty":-29.662778,"median":12.313861,"eighty":18.22447,"marketCap":2049992817},{"date":"2020-09-18","current":18.217751,"twenty":-29.662778,"median":12.50872,"eighty":18.227697,"marketCap":2078882231},{"date":"2020-09-25","current":17.306357,"twenty":-29.662778,"median":12.690857,"eighty":18.227697,"marketCap":1974880341},{"date":"2020-10-02","current":17.134205,"twenty":-29.662778,"median":12.772759,"eighty":18.227697,"marketCap":1955235539},{"date":"2020-10-09","current":18.582309,"twenty":-29.662778,"median":12.948505,"eighty":18.242559,"marketCap":2120482987},{"date":"2020-10-16","current":18.227878,"twenty":-29.662778,"median":13.039541,"eighty":18.265281,"marketCap":2080037808},{"date":"2020-10-23","current":18.075979,"twenty":-29.662778,"median":13.12871,"eighty":18.265281,"marketCap":2062704159},{"date":"2020-10-30","current":16.992433,"twenty":-29.662778,"median":13.207771,"eighty":18.265281,"marketCap":1939057467},{"date":"2020-11-06","current":19.210299,"twenty":-29.662778,"median":13.384252,"eighty":18.317545,"marketCap":2101568249},{"date":"2020-11-13","current":19.210299,"twenty":-29.662778,"median":13.650021,"eighty":18.406303,"marketCap":2101568249},{"date":"2020-11-20","current":25.411965,"twenty":-29.662778,"median":13.746278,"eighty":18.477389,"marketCap":2780018143},{"date":"2020-11-27","current":24.413752,"twenty":-29.662778,"median":13.837384,"eighty":18.52368,"marketCap":2670815591},{"date":"2020-12-04","current":25.008432,"twenty":-29.662778,"median":13.946858,"eighty":18.566015,"marketCap":2735872430},{"date":"2020-12-11","current":26.888046,"twenty":-29.662778,"median":14.03291,"eighty":18.609219,"marketCap":2941498511},{"date":"2020-12-18","current":27.88626,"twenty":-29.662778,"median":14.128307,"eighty":18.66755,"marketCap":3050701063},{"date":"2020-12-24","current":28.873854,"twenty":-29.662778,"median":14.204207,"eighty":18.752824,"marketCap":3158741885},{"date":"2020-12-31","current":27.780067,"twenty":-29.662778,"median":14.259111,"eighty":18.823955,"marketCap":3039083770},{"date":"2021-01-08","current":28.852615,"twenty":-29.662778,"median":14.437044,"eighty":18.90799,"marketCap":3156418426},{"date":"2021-01-15","current":29.882687,"twenty":-29.662778,"median":14.544352,"eighty":19.043327,"marketCap":3269106165},{"date":"2021-01-22","current":29.797732,"twenty":-29.662778,"median":14.568513,"eighty":19.173242,"marketCap":3259812331},{"date":"2021-01-29","current":30.010118,"twenty":-29.662778,"median":14.642599,"eighty":19.220775,"marketCap":3283046917},{"date":"2021-02-05","current":31.231337,"twenty":-29.662778,"median":14.727532,"eighty":19.357645,"marketCap":3416645783},{"date":"2021-02-12","current":29.734017,"twenty":-29.662778,"median":14.762883,"eighty":19.474737,"marketCap":3252841956},{"date":"2021-02-19","current":28.608372,"twenty":-29.662778,"median":14.848087,"eighty":19.754982,"marketCap":3129698653},{"date":"2021-02-26","current":27.831125,"twenty":-29.662778,"median":14.9005,"eighty":19.989119,"marketCap":2950405376},{"date":"2021-03-05","current":27.167162,"twenty":-29.662778,"median":14.992635,"eighty":20.173345,"marketCap":2880017971},{"date":"2021-03-12","current":28.428692,"twenty":-29.662778,"median":15.028869,"eighty":20.32634,"marketCap":3013754040},{"date":"2021-03-19","current":28.351229,"twenty":-29.662778,"median":15.068378,"eighty":20.471695,"marketCap":3005542176},{"date":"2021-03-26","current":27.089699,"twenty":-29.662778,"median":15.130098,"eighty":20.550186,"marketCap":2871806107},{"date":"2021-04-01","current":27.034369,"twenty":-29.662778,"median":15.171294,"eighty":20.747868,"marketCap":2865940490},{"date":"2021-04-09","current":25.09781,"twenty":-29.662778,"median":15.211446,"eighty":20.923746,"marketCap":2660643893},{"date":"2021-04-16","current":25.191871,"twenty":-29.662778,"median":15.278755,"eighty":21.20428,"marketCap":2670615442},{"date":"2021-04-23","current":26.40353,"twenty":-29.662778,"median":15.369745,"eighty":21.53034,"marketCap":2799064608},{"date":"2021-04-30","current":25.072352,"twenty":-29.662778,"median":15.47411,"eighty":22.287951,"marketCap":2657945100},{"date":"2021-05-07","current":24.754882,"twenty":-29.662778,"median":15.518576,"eighty":24.294815,"marketCap":2460907601},{"date":"2021-05-14","current":24.9074,"twenty":-29.662778,"median":15.610839,"eighty":24.413752,"marketCap":2476069591},{"date":"2021-05-21","current":25.247633,"twenty":-29.662778,"median":15.638633,"eighty":24.698476,"marketCap":2509892491},{"date":"2021-05-28","current":25.341491,"twenty":-29.662778,"median":15.686181,"eighty":24.861995,"marketCap":2519222947},{"date":"2021-06-04","current":25.11858,"twenty":-29.564231,"median":15.705567,"eighty":24.993109,"marketCap":2497063115},{"date":"2021-06-11","current":25.259366,"twenty":-29.564231,"median":15.782208,"eighty":25.114426,"marketCap":2511058798},{"date":"2021-06-18","current":26.397386,"twenty":-29.564231,"median":15.836865,"eighty":25.18427,"marketCap":2624190570},{"date":"2021-06-25","current":26.678958,"twenty":-29.564231,"median":15.876709,"eighty":25.257019,"marketCap":2652181936},{"date":"2021-07-02","current":26.174475,"twenty":-29.564231,"median":15.929368,"eighty":25.341445,"marketCap":2602030738},{"date":"2021-07-09","current":25.857706,"twenty":-29.357281,"median":15.951149,"eighty":25.408891,"marketCap":2570540451},{"date":"2021-07-16","current":23.698987,"twenty":-28.953237,"median":15.97248,"eighty":25.421286,"marketCap":2355939978},{"date":"2021-07-23","current":23.804576,"twenty":-28.83498,"median":16.047822,"eighty":25.421286,"marketCap":2366436740},{"date":"2021-07-30","current":24.668273,"twenty":7.658953,"median":16.153301,"eighty":25.421286,"marketCap":2407796084},{"date":"2021-08-06","current":25.927222,"twenty":8.529565,"median":16.182777,"eighty":25.604292,"marketCap":2530678311},{"date":"2021-08-13","current":24.561381,"twenty":8.686335,"median":16.258487,"eighty":25.617005,"marketCap":2397362687},{"date":"2021-08-20","current":24.466366,"twenty":8.870861,"median":16.364258,"eighty":25.617005,"marketCap":2388088557},{"date":"2021-08-27","current":25.570915,"twenty":9.046769,"median":16.394537,"eighty":25.617005,"marketCap":2495900322},{"date":"2021-09-03","current":25.570915,"twenty":9.231188,"median":16.443465,"eighty":25.64695,"marketCap":2495900322},{"date":"2021-09-10","current":25.06021,"twenty":9.353202,"median":16.481052,"eighty":25.64695,"marketCap":2446051871},{"date":"2021-09-17","current":24.359474,"twenty":9.563882,"median":16.545079,"eighty":25.64695,"marketCap":2377655160},{"date":"2021-09-24","current":24.098183,"twenty":9.648271,"median":16.60001,"eighty":25.64695,"marketCap":2352151302},{"date":"2021-10-01","current":23.563723,"twenty":9.818742,"median":16.632453,"eighty":25.64695,"marketCap":2299984319},{"date":"2021-10-08","current":24.157567,"twenty":9.8781,"median":16.710363,"eighty":25.642787,"marketCap":2357947633},{"date":"2021-10-15","current":23.801261,"twenty":9.911585,"median":16.806324,"eighty":25.642787,"marketCap":2323169645},{"date":"2021-10-22","current":22.233513,"twenty":10.120373,"median":16.916725,"eighty":25.642787,"marketCap":2170146494},{"date":"2021-10-29","current":21.378378,"twenty":10.16729,"median":16.975967,"eighty":25.638625,"marketCap":2086679322},{"date":"2021-11-05","current":22.428163,"twenty":10.247766,"median":17.021769,"eighty":25.638625,"marketCap":2387545188},{"date":"2021-11-12","current":24.946122,"twenty":10.405229,"median":17.108284,"eighty":25.638625,"marketCap":2655589545},{"date":"2021-11-19","current":24.805122,"twenty":10.509751,"median":17.160274,"eighty":25.638625,"marketCap":2640579691},{"date":"2021-11-26","current":23.308355,"twenty":10.517646,"median":17.193019,"eighty":25.638625,"marketCap":2481244318},{"date":"2021-12-03","current":22.679279,"twenty":10.570633,"median":17.245845,"eighty":25.638625,"marketCap":2414277277},{"date":"2021-12-10","current":20.336513,"twenty":10.633993,"median":17.285339,"eighty":25.638625,"marketCap":2164882781},{"date":"2021-12-17","current":20.45582,"twenty":10.674216,"median":17.377243,"eighty":25.638625,"marketCap":2177583426},{"date":"2021-12-23","current":19.753147,"twenty":10.722066,"median":17.416987,"eighty":25.638625,"marketCap":2102781801},{"date":"2021-12-31","current":19.703391,"twenty":10.819468,"median":17.454342,"eighty":25.638625,"marketCap":2097485121},{"date":"2022-01-07","current":18.857539,"twenty":10.913816,"median":17.567549,"eighty":25.634462,"marketCap":2007441568},{"date":"2022-01-14","current":18.359978,"twenty":11.137655,"median":17.627876,"eighty":25.634462,"marketCap":1954474772},{"date":"2022-01-21","current":17.106126,"twenty":11.176492,"median":17.634297,"eighty":25.634462,"marketCap":1820998446},{"date":"2022-01-28","current":17.524077,"twenty":11.270479,"median":17.649,"eighty":25.634462,"marketCap":1865490555},{"date":"2022-02-04","current":19.315294,"twenty":11.365143,"median":17.759255,"eighty":25.634462,"marketCap":2056171020},{"date":"2022-02-11","current":19.892464,"twenty":11.408008,"median":17.831672,"eighty":25.634462,"marketCap":2117612504},{"date":"2022-02-18","current":21.227889,"twenty":11.568834,"median":17.864938,"eighty":25.634462,"marketCap":2388392248},{"date":"2022-02-25","current":21.331486,"twenty":11.631674,"median":17.906314,"eighty":25.634462,"marketCap":2400048110},{"date":"2022-03-04","current":22.292109,"twenty":11.795058,"median":17.930398,"eighty":25.634462,"marketCap":2508129747},{"date":"2022-03-11","current":22.904271,"twenty":12.28719,"median":17.972454,"eighty":25.634462,"marketCap":2577005300},{"date":"2022-03-18","current":23.516432,"twenty":12.475052,"median":18.005093,"eighty":25.634462,"marketCap":2645880853},{"date":"2022-03-25","current":22.574645,"twenty":12.627441,"median":18.031905,"eighty":25.634462,"marketCap":2539918464},{"date":"2022-04-01","current":22.273273,"twenty":12.74917,"median":18.063294,"eighty":25.634462,"marketCap":2506010499},{"date":"2022-04-08","current":23.412836,"twenty":12.847907,"median":18.095067,"eighty":25.634462,"marketCap":2634224990},{"date":"2022-04-14","current":23.064375,"twenty":13.008366,"median":18.12447,"eighty":25.634462,"marketCap":2595018906},{"date":"2022-04-22","current":21.020696,"twenty":13.07616,"median":18.16833,"eighty":25.634462,"marketCap":2365080522},{"date":"2022-04-29","current":20.312779,"twenty":13.138468,"median":18.203209,"eighty":25.634462,"marketCap":2285431391},{"date":"2022-05-06","current":18.239814,"twenty":13.303116,"median":18.227652,"eighty":25.634462,"marketCap":2040013747},{"date":"2022-05-13","current":17.992816,"twenty":13.407715,"median":18.227652,"eighty":25.634462,"marketCap":2012388561},{"date":"2022-05-20","current":19.398802,"twenty":13.706817,"median":18.242251,"eighty":25.634462,"marketCap":2169639620},{"date":"2022-05-27","current":19.949796,"twenty":13.79308,"median":18.271684,"eighty":25.634462,"marketCap":2231265036},{"date":"2022-06-03","current":20.291793,"twenty":13.889642,"median":18.339285,"eighty":25.634462,"marketCap":2269515293},{"date":"2022-06-10","current":20.339292,"twenty":13.973328,"median":18.40556,"eighty":25.634462,"marketCap":2274827829},{"date":"2022-06-17","current":19.664799,"twenty":14.068138,"median":18.465203,"eighty":25.634462,"marketCap":2199389821},{"date":"2022-06-24","current":22.609769,"twenty":14.163827,"median":18.496311,"eighty":25.638625,"marketCap":2528767040},{"date":"2022-07-01","current":24.167753,"twenty":14.242503,"median":18.547204,"eighty":25.638625,"marketCap":2703018215},{"date":"2022-07-08","current":26.257732,"twenty":14.375881,"median":18.575405,"eighty":25.689659,"marketCap":2936769790},{"date":"2022-07-15","current":25.877736,"twenty":14.535395,"median":18.611477,"eighty":25.706312,"marketCap":2894269503},{"date":"2022-07-22","current":25.564239,"twenty":14.560417,"median":18.668127,"eighty":25.758082,"marketCap":2859206767},{"date":"2022-07-29","current":27.226722,"twenty":14.617956,"median":18.734208,"eighty":25.807402,"marketCap":3045145520},{"date":"2022-08-05","current":27.267222,"twenty":14.673898,"median":18.765235,"eighty":25.816914,"marketCap":3073915738},{"date":"2022-08-12","current":26.9917,"twenty":14.673898,"median":18.765235,"eighty":25.816914,"marketCap":3042855265},{"date":"2022-08-19","current":26.288642,"twenty":14.673898,"median":18.765235,"eighty":25.807402,"marketCap":2963597508},{"date":"2022-08-26","current":25.386069,"twenty":14.673898,"median":18.765235,"eighty":25.764749,"marketCap":2861847684},{"date":"2022-09-02","current":24.350484,"twenty":14.673898,"median":18.765235,"eighty":25.706312,"marketCap":2745103149},{"date":"2022-09-09","current":24.692512,"twenty":14.673898,"median":18.765235,"eighty":25.655304,"marketCap":2783660977},{"date":"2022-09-16","current":24.217473,"twenty":14.673898,"median":18.765235,"eighty":25.573003,"marketCap":2730108438},{"date":"2022-09-23","current":23.827942,"twenty":14.673898,"median":18.765235,"eighty":25.52154,"marketCap":2686195356},{"date":"2022-09-30","current":24.359985,"twenty":14.673898,"median":18.765235,"eighty":25.435028,"marketCap":2746174199},{"date":"2022-10-07","current":25.15805,"twenty":14.673898,"median":18.765235,"eighty":25.385744,"marketCap":2836142465},{"date":"2022-10-14","current":25.861107,"twenty":14.673898,"median":18.765235,"eighty":25.359001,"marketCap":2915400223},{"date":"2022-10-21","current":27.191216,"twenty":14.673898,"median":18.765235,"eighty":25.359001,"marketCap":3065347332},{"date":"2022-10-28","current":27.020202,"twenty":14.673898,"median":18.765235,"eighty":25.359001,"marketCap":3046068418},{"date":"2022-11-04","current":23.534301,"twenty":14.673898,"median":18.765235,"eighty":25.345826,"marketCap":2750453769},{"date":"2022-11-11","current":24.409353,"twenty":14.673898,"median":18.765235,"eighty":25.302694,"marketCap":2852721131},{"date":"2022-11-18","current":24.418564,"twenty":14.673898,"median":18.765235,"eighty":25.25389,"marketCap":2853797629},{"date":"2022-11-25","current":24.04091,"twenty":14.673898,"median":18.765235,"eighty":25.245187,"marketCap":2809661189},{"date":"2022-12-02","current":23.00927,"twenty":14.673898,"median":18.765235,"eighty":25.190124,"marketCap":2689093352},{"date":"2022-12-09","current":19.693282,"twenty":14.673898,"median":18.765235,"eighty":25.156355,"marketCap":2301553878},{"date":"2022-12-16","current":18.505053,"twenty":14.673898,"median":18.734208,"eighty":25.11858,"marketCap":2162685566},{"date":"2022-12-23","current":19.020873,"twenty":14.673898,"median":18.727537,"eighty":25.081457,"marketCap":2222969485},{"date":"2022-12-30","current":18.707697,"twenty":14.673898,"median":18.698486,"eighty":25.045958,"marketCap":2186368534},{"date":"2023-01-06","current":19.011662,"twenty":14.673898,"median":18.678417,"eighty":24.974696,"marketCap":2221892986},{"date":"2023-01-13","current":20.669656,"twenty":14.673898,"median":18.678417,"eighty":24.915538,"marketCap":2415662723},{"date":"2023-01-20","current":22.042107,"twenty":14.673898,"median":18.678417,"eighty":24.864493,"marketCap":2576061006},{"date":"2023-01-27","current":21.424965,"twenty":14.673898,"median":18.678417,"eighty":24.824329,"marketCap":2503935604},{"date":"2023-02-03","current":22.401339,"twenty":14.673898,"median":18.678417,"eighty":24.787147,"marketCap":2618044449},{"date":"2023-02-10","current":21.185477,"twenty":14.673898,"median":18.678417,"eighty":24.732601,"marketCap":2475946642},{"date":"2023-02-17","current":20.752556,"twenty":14.673898,"median":18.678417,"eighty":24.674168,"marketCap":2425351210},{"date":"2023-02-24","current":19.628805,"twenty":14.704915,"median":18.698486,"eighty":24.658704,"marketCap":2294018388},{"date":"2023-03-03","current":20.427014,"twenty":14.743485,"median":18.748075,"eighty":24.658704,"marketCap":2071666867},{"date":"2023-03-10","current":22.022874,"twenty":14.846954,"median":18.83403,"eighty":24.658704,"marketCap":2233515841},{"date":"2023-03-17","current":21.95904,"twenty":14.846954,"median":18.881519,"eighty":24.658704,"marketCap":2227041882},{"date":"2023-03-24","current":23.161255,"twenty":14.846954,"median":18.911757,"eighty":24.658704,"marketCap":2348968109},{"date":"2023-03-31","current":23.044225,"twenty":14.880165,"median":18.956878,"eighty":24.656936,"marketCap":2337099184},{"date":"2023-04-06","current":23.269603,"twenty":14.939906,"median":19.012,"eighty":24.656936,"marketCap":2359956610},{"date":"2023-04-14","current":22.558279,"twenty":14.998571,"median":19.051009,"eighty":24.658704,"marketCap":2287815518},{"date":"2023-04-21","current":22.334547,"twenty":14.998571,"median":19.104305,"eighty":24.658704,"marketCap":2265125109},{"date":"2023-04-28","current":22.344563,"twenty":14.998571,"median":19.166026,"eighty":24.658704,"marketCap":2266140860},{"date":"2023-05-05","current":25.797561,"twenty":15.006317,"median":19.199679,"eighty":24.674168,"marketCap":2437869528},{"date":"2023-05-12","current":25.70082,"twenty":15.067256,"median":19.220918,"eighty":24.732601,"marketCap":2428727517},{"date":"2023-05-19","current":25.851306,"twenty":15.164442,"median":19.305872,"eighty":24.787147,"marketCap":2442948422},{"date":"2023-05-26","current":26.356508,"twenty":15.226034,"median":19.370302,"eighty":24.824329,"marketCap":2490690034},{"date":"2023-06-02","current":24.690416,"twenty":15.273706,"median":19.394904,"eighty":24.82815,"marketCap":2333244294},{"date":"2023-06-09","current":25.840557,"twenty":15.369745,"median":19.488201,"eighty":24.87997,"marketCap":2441932643},{"date":"2023-06-16","current":24.926893,"twenty":15.394885,"median":19.593928,"eighty":24.927234,"marketCap":2355591431},{"date":"2023-06-23","current":24.023979,"twenty":15.563594,"median":19.67904,"eighty":24.927405,"marketCap":2270265997},{"date":"2023-06-30","current":23.250052,"twenty":15.628233,"median":19.743196,"eighty":24.927575,"marketCap":2197129912},{"date":"2023-07-07","current":23.615517,"twenty":15.686181,"median":19.772513,"eighty":24.927575,"marketCap":2231666397},{"date":"2023-07-14","current":24.314201,"twenty":15.761523,"median":19.849055,"eighty":24.927746,"marketCap":2297692030},{"date":"2023-07-21","current":25.077379,"twenty":15.821796,"median":19.960736,"eighty":24.935276,"marketCap":2369812337},{"date":"2023-07-28","current":26.904706,"twenty":15.876709,"median":20.074148,"eighty":25.002136,"marketCap":2542494761},{"date":"2023-08-04","current":33.858501,"twenty":15.929368,"median":20.130809,"eighty":25.06021,"marketCap":3203555971},{"date":"2023-08-11","current":33.273239,"twenty":15.97248,"median":20.230235,"eighty":25.077379,"marketCap":3148180804},{"date":"2023-08-18","current":33.067314,"twenty":16.047822,"median":20.286868,"eighty":25.09781,"marketCap":3128696949},{"date":"2023-08-25","current":34.432925,"twenty":16.153301,"median":20.335787,"eighty":25.131471,"marketCap":3257905672},{"date":"2023-09-01","current":35.473392,"twenty":16.199879,"median":20.360084,"eighty":25.165508,"marketCap":3356350414},{"date":"2023-09-08","current":35.928595,"twenty":16.288916,"median":20.424644,"eighty":25.202732,"marketCap":3399419988},{"date":"2023-09-15","current":36.633078,"twenty":16.372908,"median":20.485854,"eighty":25.247633,"marketCap":3466075282},{"date":"2023-09-22","current":34.606336,"twenty":16.402788,"median":20.528058,"eighty":25.271098,"marketCap":3274313129},{"date":"2023-09-29","current":35.755184,"twenty":16.454668,"median":20.647713,"eighty":25.318027,"marketCap":3383012531},{"date":"2023-10-06","current":28.710362,"twenty":16.484805,"median":20.739765,"eighty":25.352329,"marketCap":2716459592},{"date":"2023-10-13","current":29.935077,"twenty":16.545079,"median":20.805107,"eighty":25.396593,"marketCap":2832337257},{"date":"2023-10-20","current":30.346928,"twenty":16.62042,"median":20.91148,"eighty":25.46924,"marketCap":2871304968},{"date":"2023-10-27","current":29.870048,"twenty":16.635578,"median":20.971474,"eighty":25.500078,"marketCap":2826184461},{"date":"2023-11-03","current":28.378566,"twenty":16.744505,"median":21.039532,"eighty":25.568245,"marketCap":2593403665},{"date":"2023-11-10","current":28.097921,"twenty":16.816673,"median":21.093333,"eighty":25.60843,"marketCap":2567756602},{"date":"2023-11-17","current":28.323516,"twenty":16.948321,"median":21.176265,"eighty":25.655139,"marketCap":2588372874},{"date":"2023-11-24","current":28.571672,"twenty":16.9786,"median":21.207187,"eighty":25.701265,"marketCap":2611050772},{"date":"2023-12-01","current":28.729588,"twenty":17.023968,"median":21.222783,"eighty":25.744003,"marketCap":2625482162},{"date":"2023-12-08","current":30.15084,"twenty":17.075645,"median":21.281808,"eighty":25.795392,"marketCap":2755364672},{"date":"2023-12-15","current":33.647571,"twenty":17.145357,"median":21.387263,"eighty":25.809981,"marketCap":3074916879},{"date":"2023-12-22","current":35.711769,"twenty":17.182275,"median":21.514351,"eighty":25.859066,"marketCap":3263555762},{"date":"2023-12-29","current":37.087902,"twenty":17.245845,"median":21.57635,"eighty":25.875763,"marketCap":3389315018},{"date":"2024-01-05","current":28.582951,"twenty":17.249581,"median":21.617351,"eighty":25.902621,"marketCap":2612081586},{"date":"2024-01-12","current":26.451074,"twenty":17.300075,"median":21.662782,"eighty":26.071548,"marketCap":2417257821},{"date":"2024-01-19","current":27.906165,"twenty":17.358343,"median":21.792961,"eighty":26.115814,"marketCap":2550232772},{"date":"2024-01-26","current":25.898365,"twenty":17.391973,"median":21.940702,"eighty":26.170789,"marketCap":2366747956},{"date":"2024-02-02","current":24.398155,"twenty":17.425443,"median":22.062266,"eighty":26.170789,"marketCap":2229649751},{"date":"2024-02-09","current":25.368215,"twenty":17.524077,"median":22.147709,"eighty":26.170789,"marketCap":2318299718},{"date":"2024-02-16","current":23.855618,"twenty":17.589266,"median":22.21893,"eighty":26.191114,"marketCap":2532035310},{"date":"2024-02-23","current":22.42194,"twenty":17.626358,"median":22.234584,"eighty":26.191114,"marketCap":2379864750},{"date":"2024-03-01","current":22.919339,"twenty":17.633519,"median":22.273273,"eighty":26.186954,"marketCap":2432658618},{"date":"2024-03-08","current":22.802304,"twenty":17.633519,"median":22.340405,"eighty":26.186954,"marketCap":2420236531},{"date":"2024-03-15","current":23.085138,"twenty":17.633519,"median":22.41652,"eighty":26.186954,"marketCap":2450256573},{"date":"2024-03-22","current":24.138453,"twenty":17.633519,"median":22.460952,"eighty":26.186954,"marketCap":2562055353},{"date":"2024-03-28","current":24.694368,"twenty":17.690591,"median":22.494795,"eighty":26.186954,"marketCap":2621060264},{"date":"2024-04-05","current":24.43104,"twenty":17.751499,"median":22.557044,"eighty":26.191114,"marketCap":2593110569},{"date":"2024-04-12","current":23.303197,"twenty":17.751499,"median":22.576228,"eighty":26.191114,"marketCap":2473401294},{"date":"2024-04-19","current":22.168364,"twenty":17.751499,"median":22.605072,"eighty":26.191114,"marketCap":2352950181},{"date":"2024-04-26","current":21.728128,"twenty":17.75667,"median":22.602899,"eighty":26.186954,"marketCap":2306223456},{"date":"2024-05-03","current":22.106275,"twenty":17.75667,"median":22.608023,"eighty":26.186954,"marketCap":2609048925},{"date":"2024-05-10","current":23.464761,"twenty":17.774039,"median":22.609769,"eighty":26.186954,"marketCap":2769381540},{"date":"2024-05-17","current":24.293967,"twenty":17.84352,"median":22.678242,"eighty":26.186954,"marketCap":2867246903},{"date":"2024-05-24","current":24.558607,"twenty":17.897853,"median":22.753585,"eighty":26.186954,"marketCap":2898480529},{"date":"2024-05-31","current":27.531399,"twenty":17.929134,"median":22.805275,"eighty":26.264877,"marketCap":3249338266},{"date":"2024-06-07","current":30.415976,"twenty":17.97088,"median":22.828928,"eighty":26.281877,"marketCap":3589784794},{"date":"2024-06-14","current":27.796039,"twenty":18.005093,"median":22.893398,"eighty":26.32196,"marketCap":3280571892},{"date":"2024-06-21","current":25.934736,"twenty":18.025346,"median":22.970196,"eighty":26.326142,"marketCap":3060895387},{"date":"2024-06-28","current":28.281212,"twenty":18.058813,"median":23.010789,"eighty":26.361392,"marketCap":3337833541},{"date":"2024-07-05","current":26.905084,"twenty":18.08407,"median":23.045023,"eighty":26.401346,"marketCap":3175418684},{"date":"2024-07-12","current":27.496113,"twenty":18.125253,"median":23.112931,"eighty":26.435971,"marketCap":3245173782},{"date":"2024-07-15","current":27.787218,"twenty":18.151583,"median":23.125276,"eighty":26.439168,"marketCap":3279530772},{"date":"2024-08-02","current":31.468089,"twenty":18.227878,"median":23.207056,"eighty":26.472425,"marketCap":3964444273},{"date":"2024-08-09","current":28.258245,"twenty":18.289588,"median":23.250052,"eighty":26.573962,"marketCap":3560058418},{"date":"2024-08-16","current":28.979837,"twenty":18.299654,"median":23.308355,"eighty":26.638271,"marketCap":3650966866},{"date":"2024-08-23","current":28.432422,"twenty":18.299654,"median":23.412836,"eighty":26.737384,"marketCap":3582001837},{"date":"2024-08-30","current":29.145721,"twenty":18.420312,"median":23.48289,"eighty":26.875577,"marketCap":3671865360},{"date":"2024-09-06","current":28.283127,"twenty":18.479546,"median":23.50276,"eighty":26.907206,"marketCap":3563193192},{"date":"2024-09-13","current":29.618489,"twenty":18.489602,"median":23.553278,"eighty":26.969813,"marketCap":3731426067},{"date":"2024-09-20","current":33.939752,"twenty":18.489602,"median":23.628594,"eighty":27.012802,"marketCap":4275831831},{"date":"2024-09-27","current":35.897177,"twenty":18.489602,"median":23.704432,"eighty":27.065252,"marketCap":4522434058},{"date":"2024-10-04","current":37.356951,"twenty":18.489602,"median":23.766003,"eighty":27.198317,"marketCap":4706340803},{"date":"2024-10-11","current":37.531129,"twenty":18.489602,"median":23.79825,"eighty":27.269122,"marketCap":4728284222},{"date":"2024-10-18","current":39.12361,"twenty":18.489602,"median":23.827222,"eighty":27.390639,"marketCap":4928909762},{"date":"2024-10-25","current":39.181669,"twenty":18.489602,"median":23.839773,"eighty":27.531768,"marketCap":4936224235},{"date":"2024-10-31","current":34.548872,"twenty":18.489602,"median":23.855618,"eighty":27.607335,"marketCap":4899651871},{"date":"2024-11-08","current":40.116839,"twenty":18.488035,"median":23.944067,"eighty":27.690634,"marketCap":5689289939},{"date":"2024-11-15","current":40.478851,"twenty":18.488035,"median":24.018628,"eighty":27.792827,"marketCap":5740629756},{"date":"2024-11-22","current":41.313695,"twenty":18.501556,"median":24.046375,"eighty":27.825976,"marketCap":5859025661},{"date":"2024-11-29","current":42.613983,"twenty":18.57617,"median":24.098183,"eighty":27.94226,"marketCap":6043429902},{"date":"2024-12-06","current":43.899495,"twenty":18.605886,"median":24.135934,"eighty":28.081714,"marketCap":6225738640},{"date":"2024-12-13","current":41.612909,"twenty":18.704013,"median":24.157567,"eighty":28.205158,"marketCap":5901459591},{"date":"2024-12-20","current":37.789619,"twenty":18.861587,"median":24.179738,"eighty":28.267432,"marketCap":5359248257},{"date":"2024-12-27","current":39.621843,"twenty":18.901855,"median":24.222326,"eighty":28.295017,"marketCap":5619090597},{"date":"2025-01-03","current":36.917836,"twenty":18.962014,"median":24.246775,"eighty":28.334601,"marketCap":5235613595},{"date":"2025-01-10","current":38.188571,"twenty":19.031446,"median":24.276325,"eighty":28.377038,"marketCap":5415826831},{"date":"2025-01-17","current":40.220271,"twenty":19.099543,"median":24.296939,"eighty":28.43093,"marketCap":5703958458},{"date":"2025-01-24","current":46.019851,"twenty":19.160732,"median":24.33572,"eighty":28.461514,"marketCap":6526443283},{"date":"2025-01-31","current":51.642119,"twenty":19.203927,"median":24.359985,"eighty":28.529757,"marketCap":7323782076},{"date":"2025-02-07","current":50.267951,"twenty":19.239158,"median":24.395104,"eighty":28.578439,"marketCap":7128900321},{"date":"2025-02-14","current":54.383067,"twenty":19.337603,"median":24.413752,"eighty":28.61904,"marketCap":7712497834},{"date":"2025-02-21","current":48.088491,"twenty":19.396463,"median":24.43104,"eighty":28.65241,"marketCap":6819813667},{"date":"2025-02-28","current":44.716558,"twenty":19.542449,"median":24.466366,"eighty":28.709029,"marketCap":6314380405},{"date":"2025-03-07","current":40.56991,"twenty":19.695185,"median":24.537351,"eighty":28.774142,"marketCap":5728836357},{"date":"2025-03-14","current":40.980839,"twenty":19.748215,"median":24.572457,"eighty":28.848313,"marketCap":5786863245},{"date":"2025-03-21","current":43.028013,"twenty":19.828981,"median":24.656668,"eighty":28.895923,"marketCap":6075942648},{"date":"2025-03-28","current":42.348112,"twenty":20.044795,"median":24.686713,"eighty":29.033234,"marketCap":5979934525},{"date":"2025-04-04","current":59.300805,"twenty":20.122482,"median":24.719586,"eighty":29.225898,"marketCap":8373807397},{"date":"2025-04-11","current":50.604051,"twenty":20.229693,"median":24.759018,"eighty":29.315721,"marketCap":7145747449},{"date":"2025-04-17","current":48.265491,"twenty":20.286086,"median":24.779141,"eighty":29.454515,"marketCap":6815521707}],"updateTime":1745134326605}}}